Skip to main content

Dorsey Brian's Form 4 filing

ARS Pharmaceuticals, Inc. (SPRY) · filed Dec 13, 2024

Accession no.
0001415889-24-029376
Filed
Dec 13, 2024
Trade date
Dec 11-12, 2024
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $493.9K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Dorsey BrianCIK 0001380762Officer (Chief Operating Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 11, 2024Common StockMOption exerciseAcquired+15,000$0.64+$9,60021,024Direct
Dec 11, 2024Common StockSSaleDisposed−15,000$12.43−$186,4506,024Direct
Dec 12, 2024Common StockMOption exerciseAcquired+25,000$0.64+$16,00031,024Direct
Dec 12, 2024Common StockSSaleDisposed−25,000$12.30−$307,5006,024Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 11, 2024Common StockMOption exerciseDisposed−15,000$0.00$046,828Direct
Dec 12, 2024Common StockMOption exerciseDisposed−25,000$0.00$021,828Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)